Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that antisense oligonucleotides can significantly reduce androgen receptor expression in cultured human sebocytes and may offer new therapeutic possibilities for androgen-associated skin diseases.

This paper provides a comprehensive list of drugs including Ethamolin, Placidyl, Trecator-SC, Zarontin, Peganone, Didronel, and Lodine, detailing their indications, potential interactions, and reported adverse skin reactions, but it presents no new research findings.

This study found that for men with moderate-to-severe LUTS/BPH, 6 months of treatment with tamsulosin plus the hexanic extract of S. repens was as effective as tamsulosin plus a 5-alpha-reductase inhibitor but had better tolerability.

This study identified ten novel compounds that may effectively target steroid 5 alpha-reductase 2 (5αR-2) for potential treatment of benign prostate hyperplasia, exhibiting comparable binding energies to existing drugs like finasteride and dutasteride.

This review reported that spironolactone, used off-label, is an effective and safe treatment option for adult women with acne, presenting fewer adverse reactions compared to common treatments like antimicrobials, which carry the risk of microbial resistance.

This article discusses the paradoxical effects of valproic acid on hair, reporting both drug-induced hair loss and the potential for hair growth when used topically, but presents no original research findings.

Medroxyprogesterone acetate improved sleep apnea symptoms in some obese patients.

In this study, FMN was found to inhibit androgen receptor function and androgen-regulated gene expression in prostate cancer cells, suggesting potential as an antiandrogen therapy.

This study found that in non-obese women with moderate body hair growth, DHEA-S and prolactin levels were higher, and SBP was lower compared to controls, which may inform treatment decisions.

This review discusses trials on therapies for benign prostatic hyperplasia and reports that combination treatment is more effective than monotherapy for symptom relief and slowing disease progression in men with moderate to severe symptoms and enlarged prostate glands.

This study reported that cognitive biopsy diagnosed prostate cancer in 44% of patients with at least one previous negative biopsy, with higher detection rates in lesions classified as PI-RADS 4 and 5.

This study discovered that the disposition of LY191704 enantiomers in rats and dogs is both stereoselective and species specific.

This study reported that etrasimod did not achieve significant improvements in hair regrowth for moderate to severe alopecia areata at 24 weeks, although it showed a dose-dependent trend and was safe and well-tolerated over 52 weeks.

This paper discusses a structure-based analysis to find new BRD4 inhibitors, identifying finasteride and amentoflavone as promising candidates for BET inhibition.

This report details a case of hair, nail, and pigmentary disorders occurring 10 months after starting abemaciclib for metastatic breast cancer, highlighting that cutaneous side effects, although less frequent, can lead to discontinuation in 25% of cases.

In this study, the use of 5-α reductase inhibitors was not associated with an increased risk of anaemia compared to α-blockers in men with benign prostatic hyperplasia.

This study found that 17β-estradiol was the most powerful hormone for inducing APE1/Ref-1 secretion in cultured vascular endothelial cells, with secretion occurring through exosomes dependent on estrogen receptors and intracellular calcium.

In this study, researchers reported that both progestin-only injectable contraceptives, DMPA-IM and NET-EN, significantly decreased serum testosterone and SHBG levels among HIV-negative women in South Africa, yet this did not explain prior findings of no reduction in risky sexual behavior or sexual function.

This study found that combination therapy with doxazosin and finasteride was more effective in preventing the clinical progression of benign prostatic hyperplasia than either drug alone.

This review discusses trends in testosterone therapy use for male hypogonadism and reports no new clinical results, noting a shift towards more convenient and physiological treatments.

This study developed dissolving microneedles incorporating a new AR degrader for treating androgenetic alopecia, showing that a single application leads to superior hair regeneration compared to daily minoxidil, without systemic toxicity or androgen-related issues.

This study identified distinct and significant adverse event patterns across different drug classes used to treat benign prostatic hyperplasia, confirming known risks and suggesting novel safety signals for further investigation.

This study identified that derivatives 4, 4b, and 4c strongly inhibited the enzyme type 1 5α-reductase and decreased reproductive organ weights in hamsters, suggesting potential as prodrugs for prostate tumor growth inhibition.

This study found that the monophasic oral contraceptive ethinylestradiol/chlormadinone acetate was more effective in treating mild to moderate papulopustular acne in women than ethinylestradiol/levonorgestrel.

This study found that castration-resistant prostate cancers resistant to CYP17A1 inhibitors may still depend on steroids and could respond to therapies targeting de novo intratumoral steroid synthesis.

This study found that sorafenib was active against desmoid tumors, with 25% of patients achieving a partial response and 70% maintaining stable disease.

In this study, researchers identified compound 30a as a promising topical androgen receptor antagonist that promoted hair growth in mouse models of androgenetic alopecia without noticeable toxicity, suggesting its potential for treating this hair loss condition.

This study found that dihydrotestosterone (DHT) suppresses prostaglandin E2 and TGF-β induced IGF-I gene promoter activity in osteoblasts, suggesting complex interactions among bone growth regulators and potential complications from anabolic steroid use.

In this case report, a 67-year-old woman experienced patchy hair loss, likely related to denosumab treatment for osteoporosis, as other potential causes were ruled out; stopping denosumab led to hair regrowth following intralesional triamcinolone treatment, suggesting a potential denosumab-induced alopecia areata.